Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
MarketBeat on MSN2d
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
Fierce Pharma2d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Endpoints News6d
No­vo Nordisk looks in­to start­ing GLP-1 drug tri­als for ad­dic­tion
Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.
Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
Giftify, Inc. Reports Surge in Pharmacy Retailer Gift Card Demand Following GLP-1 Medication Savings Initiative
Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving SolutionsSurge Driven by Ozempic and Zepbound Prescription ...
BioSpace3d
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...